Neutralizing the GBS hemolytic lipid toxin

Ended Project Grant Awarded Last action

Award ID
R01AI167421
Recipient
Awarding agency
Obligated
$7,346,072

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Place of performance
Washington, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Human morbidity and mortality due to bacterial infections continue to remain significant public health concern. Group b streptococcus (GBS) or streptococcus agalactiae cause invasive infections during pregnancy leading to preterm births, stillbirths or infections in newborns. Furthermore, GBS also cause infections in the normal, elderly, diabetic and immuno-compromised adults. Our work has shown that the hemolysin, which is a key virulence factor for GBS infections is a pigmented ornithine rhamnolipid also known as granadaene. This hemolytic lipid toxin is cytotoxic to a number of host cells leading to adverse outcomes to newborns and adult humans. The objectives of this proposal are to identify additional nontoxic analogs that can prevent toxin function during GBS infections using murine models of infection, to elucidate host immune mechanisms important for analog mediated immunity against this GBS toxin, to determine how membrane vesicles exacerbate GBS pathogenesis and if antibodies can attenuate their effects. Collectively, the results from these aims will be important and relevant for prevention of GBS infections in humans and will be relevant to other diseases caused by pathogens encoding toxic lipids.

Transactions

Action Obligated Date
Amendment $0
Amendment $1,620,448
Amendment $0
Amendment $1,620,448
Amendment $0
Amendment $846,792
Amendment $823,275
Amendment $823,275
Amendment $805,917
Original award $805,917

Subawards

Subrecipient Amount Awarded
Universidad De Granada Dr. Juan M. Cuerva’s group will prepare analogs of GBS pigment of different nature and will ship these (when available) to the Rajagopal lab for the… $248,400
Universidad De Granada $216,000

Quick answers

Who received award R01AI167421?

R01AI167421 was awarded to Seattle Children's Hospital by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 16, 2022.

How much is award R01AI167421 worth?

$7,346,072 has been obligated on R01AI167421.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login